NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
STRR
Star Equity Holdings, Inc.
There isn't enough reported data to score STRR yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
STRR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
STRR's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
STRR PE Valuation
STRR has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
STRR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
STRR has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over STRR on earnings quality, reporting a profit while its opponent remains loss making.
STRR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.50 | — |
| Q3 2026 | -$2.43 | -$0.86 |
| Q2 2026 | -$2.54 | -$1.23 |
| Q1 2026 | -$2.27 | -$1.04 |
| Q4 2025 | -$1.85 | -$0.26 |
| Q3 2025 | -$1.57 | -$0.43 |
| Q2 2025 | -$1.31 | -$0.62 |
| Q1 2025 | -$1.23 | -$0.87 |
| Q4 2024 | -$1.59 | -327% |
STRR lost $2.43 per share over the past year, a bigger loss than the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over STRR on profitability, with a higher operating margin.
STRR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $53.9M | +12% |
| Q2 2026 | $54.9M | +55% |
| Q1 2026 | $50.1M | +57% |
| Q4 2025 | $56.8M | +69% |
| Q3 2025 | $48M | +30% |
| Q2 2025 | $35.5M | -0.5% |
| Q1 2025 | $31.9M | -6% |
| Q4 2024 | $33.6M | -1.1% |
STRR's revenue has grown year over year for five quarters in a row: $54M last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3.4% | +0.1 points |
| Q2 2026 | -2.5% | -1.9 points |
| Q1 2026 | -8% | -2.6 points |
| Q4 2025 | -0.2% | +0.2 points |
| Q3 2025 | -3.4% | -2.2 points |
| Q2 2025 | -0.6% | -0.1 points |
| Q1 2025 | -5.4% | +3.6 points |
| Q4 2024 | -0.4% | +3.4 points |
STRR's operating margin was −3.4% last quarter, about level with the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over STRR on cash generation, producing positive trailing cash flow while its opponent burns cash.
STRR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $60K | +$3.4M |
| Q2 2026 | -$3.2M | -3269% |
| Q1 2026 | -$2.7M | -$1.9M |
| Q4 2025 | -$4.9M | -342% |
| Q3 2025 | -$3.4M | -368% |
| Q2 2025 | $102K | +$4.4M |
| Q1 2025 | -$808K | +$986K |
| Q4 2024 | $2M | -39% |
STRR's free cash flow was −$11M over the past year, against −$2M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over STRR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
STRR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -3K shares |
| 1 year | +13% | +438K shares |
| 3 years | +18% | +560K shares |
| 5 years | +22% | +679K shares |
| Available history | +18% | +570K shares |
STRR has 4M diluted shares, up 13% from a year ago, despite $1M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $306,000 |
| Q2 2026 | $157,000 |
| Q1 2026 | $712,000 |
| Q4 2025 | $66,000 |
| Q3 2025 | $2.6M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
STRR spent $1M buying back its own shares over the past year, down 52% from the year before.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
STRR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | -7.9x | Net Cash |
| Q3 2023 | -4.6x | Net Cash |
| Q2 2023 | -4.9x | Net Cash |
| Q1 2023 | -2.9x | Net Cash |
| Q4 2022 | -2.4x | Net Cash |
| Q3 2022 | -1.7x | Net Cash |
| Q2 2022 | -1.9x | Net Cash |
| Q1 2022 | -2.0x | Net Cash |
STRR has more cash than debt.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
STRR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.3 | Neutral |
| Stochastic | 26.2 | Neutral |
STRR's weekly RSI is 48 (neutral) and its Stochastic is 26 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
STRR PE vs Healthcare Sector
| Metric | STRR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
STRR has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
STRR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.84 | 1.6% above |
| 20 week MA | $10.3 | 2.9% below |
| 50 week MA | $10.3 | 3.1% below |
| 100 week MA | $10.4 | 3.6% below |
| 200 week MA | $14.2 | 30% below |
STRR has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 30% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
STRR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.5 | $10.7 | -14% |
| 2021 | $10.7 | $27.4 | +155% |
| 2022 | $27.4 | $23.5 | -14% |
| 2023 | $23.5 | $15.5 | -34% |
| 2024 | $15.5 | $13.4 | -14% |
| 2025 | $13.4 | $10.9 | -18% |
| 2026 YTD | $10.9 | $10.0 | -8.4% |
STRR has the edge over NVO on returns for 2026, with the stronger performance.